Dr Agarwals Eye Hospital Ltd Gains 6.16%: 6 Key Factors Driving the Week’s Momentum

Mar 14 2026 01:07 PM IST
share
Share Via
Dr Agarwals Eye Hospital Ltd delivered a robust weekly performance, rising 6.16% from Rs.4,474.55 to Rs.4,750.30 between 9 and 13 March 2026, significantly outperforming the Sensex which declined 4.87% over the same period. The stock’s trajectory was shaped by a series of technical shifts, valuation reassessments, and notable intraday rallies, reflecting a complex but cautiously optimistic market sentiment.

Key Events This Week

Mar 09: Stock opens at Rs.4,500.75 amid Sensex decline

Mar 10: Intraday high surge of 7.05%, closing at Rs.4,779.00

Mar 11: Upgrade to Hold rating and mixed technical signals

Mar 12: Continued price gains to Rs.4,900.70

Mar 13: Death Cross formation signals bearish trend; stock closes at Rs.4,750.30

Week Open
Rs.4,474.55
Week Close
Rs.4,750.30
+6.16%
Week High
Rs.4,900.70
vs Sensex
+11.03%

March 9: Modest Start Amid Broad Market Weakness

Dr Agarwals Eye Hospital Ltd began the week at Rs.4,500.75, marking a 0.59% gain from the previous close despite the Sensex falling 1.91% to 34,557.39. The stock’s resilience contrasted with the broader market’s weakness, signalling early investor interest. Volume was moderate at 4,955 shares, indicating steady participation.

March 10: Intraday Surge and Intriguing Technical Signals

The stock surged 6.18% to close at Rs.4,779.00, hitting an intraday high of Rs.4,818.60, a 7.05% increase from the prior close. This rally outpaced the Sensex’s 1.30% gain, highlighting strong buying momentum. The stock’s price moved above its 5-day and 20-day moving averages, signalling short-term bullishness. However, longer-term technical indicators remained mixed, with weekly and monthly momentum oscillators showing bearish tendencies.

MarketsMOJO downgraded the stock to a Sell rating prior to this day’s close but swiftly upgraded it to Hold on 11 March, reflecting the evolving technical and valuation landscape.

Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!

  • - Clear entry/exit targets
  • - Target price revealed
  • - Detailed report available

View Target Price Report →

March 11: Upgrade to Hold and Mixed Technical Momentum

On 11 March, Dr Agarwals Eye Hospital Ltd’s rating was upgraded from Sell to Hold by MarketsMOJO, reflecting improved technicals and fair valuation metrics. The stock closed at Rs.4,801.30, a 0.47% gain from the previous day, with a notable intraday range between Rs.4,600.00 and Rs.4,820.05.

Financially, the company showed strong fundamentals with 39.32% PAT growth over nine months and an operating profit surge of 83.03%. Valuation metrics shifted from attractive to fair, with a P/E ratio of 33.20, moderate compared to sector peers. Technical indicators presented a nuanced picture: daily moving averages turned mildly bullish, but weekly MACD and KST remained bearish, signalling a sideways momentum trend.

March 12: Continued Gains Amid Market Volatility

The stock advanced 2.07% to Rs.4,900.70, outperforming the Sensex which declined 0.66%. This marked the week’s high close, supported by positive short-term momentum. Despite this, technical indicators remained mixed, with Bollinger Bands mildly bearish weekly but bullish monthly, suggesting potential for further gains tempered by volatility.

Is Dr Agarwals Eye Hospital Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!

  • - Better alternatives suggested
  • - Cross-sector comparison
  • - Portfolio optimization tool

Find Better Alternatives →

March 13: Death Cross Formation and Bearish Signals

The week closed with a 3.07% decline to Rs.4,750.30, coinciding with the formation of a Death Cross—a bearish technical indicator where the 50-day moving average crosses below the 200-day moving average. This signals potential medium- to long-term weakness. Despite this, the stock’s one-year return remains strong at 8.11%, outperforming the Sensex’s 1.00% gain.

Technical momentum indicators such as MACD and KST remain bearish weekly and mildly bearish monthly, while RSI is neutral. The stock’s valuation remains fair with a P/E of 33.21, lower than many hospital sector peers. The MarketsMOJO Mojo Score stands at 51.0 with a Hold rating, reflecting cautious optimism amid technical headwinds.

Date Stock Price Day Change Sensex Day Change
2026-03-09 Rs.4,500.75 +0.59% 34,557.39 -1.91%
2026-03-10 Rs.4,779.00 +6.18% 35,005.20 +1.30%
2026-03-11 Rs.4,801.30 +0.47% 34,529.78 -1.36%
2026-03-12 Rs.4,900.70 +2.07% 34,300.49 -0.66%
2026-03-13 Rs.4,750.30 -3.07% 33,516.43 -2.29%

Key Takeaways

Positive Signals: The stock outperformed the Sensex by over 11% during the week, demonstrating resilience amid a broadly declining market. The upgrade from Sell to Hold by MarketsMOJO reflects improved fundamentals and fair valuation. Strong financial metrics, including 39.32% PAT growth and robust operating profit expansion, underpin the company’s stability. Daily moving averages turned bullish, supporting short-term momentum.

Cautionary Notes: The formation of a Death Cross on 13 March signals potential bearish momentum ahead, suggesting medium- to long-term technical weakness. Mixed technical indicators, including bearish weekly MACD and KST, counsel prudence. The stock’s valuation, while fair relative to peers, is elevated compared to its historical averages. Promoter share pledging remains a risk factor to monitor.

Conclusion

Dr Agarwals Eye Hospital Ltd’s week was marked by strong price gains and significant technical developments. The stock’s 6.16% weekly rise amid a 4.87% Sensex decline highlights its relative strength. The upgrade to a Hold rating and fair valuation grade reflect a balanced outlook, supported by solid financial performance. However, the emergence of the Death Cross and mixed momentum indicators suggest caution is warranted. Investors should monitor technical signals closely while considering the company’s impressive long-term growth record and recent operational improvements.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News